ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive AMI, and these were carried out in the era before AMI was diagnosed with biomarkers and prior to treatment with coronary angioplasty, use of antithrombotic agents and high intensity statins, and angiotensin-aldosterone system inhibitors.

ACC 2024

The aim of this multicenter, randomized study was to assess the potential benefit of treatment with beta-blockers after AMI in patients with conserved left ventricular systolic function in the current era of percutaneous treatment and medical treatment. 

The primary outcome was a combination of all-cause death and non-fatal AMI. Secondary end point was a combination of all-cause death, AMI and hospitalization for cardiac failure. There was a safety end point including hospitalization for bradyarrhythmia, hypotension or syncope, hospitalization for asthma or COPD and hospitalization for stroke. 

5020 patients were randomized; 2508 to receiving beta-blockers (metoprolol or bisoprolol) and 2512 for conventional treatment. Mean age was 65 and most were men. Mean followup was 3.5 years. 35% of patients presented ST elevation AMI. 17% presented left main and three vessel disease, and most received percutaneous coronary intervention (PCI) (96%), while the remaining 4% underwent myocardial revascularization surgery (CABG).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

The primary outcome resulted 7.9% for the beta-blocker group vs. 8.3% for the conventional treatment group (HR 0.96; CI 95% 0.79-1.16; p=0.64). There were no differences in secondary and safety end points.

Conclusion 

Among patients with acute myocardial infarction undergoing early coronary angiography with conserved left ventricular ejection fraction (≥50%), treatment with beta-blockers at long term did not present lower risk of all cause death or new AMI or new myocardial infarction vs. no beta-blockers. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Beta-blockers after Myocardial Infarction and Preserved Ejection Fraction.

Reference: Troels Yndigegn et al ACC 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...